| Year |
Citation |
Score |
| 2023 |
Pardridge WM. Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport. Frontiers in Aging Neuroscience. 15: 1276376. PMID 38035276 DOI: 10.3389/fnagi.2023.1276376 |
0.352 |
|
| 2023 |
Pardridge WM. Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier. Frontiers in Drug Delivery. 3. PMID 37583474 DOI: 10.3389/fddev.2023.1227816 |
0.394 |
|
| 2023 |
Pardridge WM. Brain gene therapy with Trojan horse lipid nanoparticles. Trends in Molecular Medicine. PMID 36907687 DOI: 10.1016/j.molmed.2023.02.004 |
0.428 |
|
| 2023 |
Pardridge WM. Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharmaceutical Research. 40: 661-674. PMID 36829100 DOI: 10.1007/s11095-023-03484-2 |
0.417 |
|
| 2022 |
Pardridge WM. Advanced Blood-Brain Barrier Drug Delivery. Pharmaceutics. 15. PMID 36678722 DOI: 10.3390/pharmaceutics15010093 |
0.385 |
|
| 2022 |
Pardridge WM. A Historical Review of Brain Drug Delivery. Pharmaceutics. 14. PMID 35745855 DOI: 10.3390/pharmaceutics14061283 |
0.409 |
|
| 2022 |
Pardridge WM. Vector-mediated peptide drug delivery to the brain. Advanced Drug Delivery Reviews. 15: 109-146. PMID 35524386 |
0.422 |
|
| 2022 |
Pardridge WM. Preface: Overview of brain drug delivery. Advanced Drug Delivery Reviews. 15: 1-3. PMID 35524385 |
0.386 |
|
| 2022 |
Pardridge WM. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. Advanced Drug Delivery Reviews. 184: 114234. PMID 35307484 DOI: 10.1016/j.addr.2022.114234 |
0.409 |
|
| 2021 |
Pardridge WM. Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor. Pharmaceuticals (Basel, Switzerland). 15. PMID 35056060 DOI: 10.3390/ph15010003 |
0.425 |
|
| 2021 |
Pardridge WM, Chou T. Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor. Pharmaceuticals (Basel, Switzerland). 14. PMID 34205013 DOI: 10.3390/ph14060535 |
0.335 |
|
| 2020 |
Pardridge WM. Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain. Frontiers in Medical Technology. 2: 602236. PMID 35047884 DOI: 10.3389/fmedt.2020.602236 |
0.463 |
|
| 2020 |
Jiang D, Lee H, Pardridge WM. Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes. Scientific Reports. 10: 13334. PMID 32770132 DOI: 10.1038/S41598-020-70290-W |
0.36 |
|
| 2020 |
Pardridge WM. The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier. Frontiers in Physiology. 11: 398. PMID 32457645 DOI: 10.3389/fphys.2020.00398 |
0.534 |
|
| 2019 |
Pardridge WM. Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. Frontiers in Aging Neuroscience. 11: 373. PMID 31998120 DOI: 10.3389/fnagi.2019.00373 |
0.47 |
|
| 2019 |
Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM. Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery. Scientific Reports. 9: 18632. PMID 31819150 DOI: 10.1038/s41598-019-55136-4 |
0.313 |
|
| 2019 |
Chang R, Al Maghribi A, Vanderpoel V, Vasilevko V, Cribbs DH, Boado R, Pardridge WM, Sumbria RK. A Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. Molecular Pharmaceutics. PMID 31804843 DOI: 10.1021/acs.molpharmaceut.9b01211 |
0.392 |
|
| 2019 |
Sun J, Yang J, Whitman K, Zhu C, Cribbs DH, Boado RJ, Pardridge WM, Sumbria RK. Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice. Alzheimer's & Dementia (New York, N. Y.). 5: 627-636. PMID 31660425 DOI: 10.1016/j.trci.2019.09.003 |
0.353 |
|
| 2019 |
Pardridge WM. Alzheimer's disease: future drug development and the blood-brain barrier. Expert Opinion On Investigational Drugs. 1-4. PMID 31155971 DOI: 10.1080/13543784.2019.1627325 |
0.365 |
|
| 2018 |
Chang R, Maghribi AA, Vanderpoel V, Vasilevko V, Cribbs DH, Boado R, Pardridge WM, Sumbria RK. A Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. Molecular Pharmaceutics. PMID 30252487 DOI: 10.1021/acs.molpharmaceut.8b00594 |
0.413 |
|
| 2018 |
Pardridge WM, Boado RJ, Patrick DJ, Hui EK, Lu JZ. Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the Rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor. Molecular Pharmaceutics. PMID 30226787 DOI: 10.1021/acs.molpharmaceut.8b00730 |
0.413 |
|
| 2018 |
Pardridge WM, Boado RJ, Giugliani R, Schmidt M. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 32: 169-176. PMID 29442294 DOI: 10.1007/s40259-018-0264-7 |
0.337 |
|
| 2017 |
Boado RJ, Lu JZ, Hui EK, Pardridge WM. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamindase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. Molecular Pharmaceutics. PMID 29251941 DOI: 10.1021/acs.molpharmaceut.7b00958 |
0.435 |
|
| 2017 |
Pardridge WM. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 31: 503-519. PMID 29067674 DOI: 10.1007/s40259-017-0248-z |
0.438 |
|
| 2017 |
Boado RJ, Pardridge WM. Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. Molecular Pharmaceutics. 14: 1271-1277. PMID 28279069 DOI: 10.1021/acs.molpharmaceut.6b01166 |
0.497 |
|
| 2016 |
Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies. Expert Opinion On Biological Therapy. PMID 27572805 DOI: 10.1080/14712598.2016.1230195 |
0.32 |
|
| 2016 |
Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opinion On Drug Delivery. 13: 963-75. PMID 27020469 DOI: 10.1517/17425247.2016.1171315 |
0.445 |
|
| 2016 |
Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM. Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts. Molecular Pharmaceutics. PMID 26910785 DOI: 10.1021/acs.molpharmaceut.6b00037 |
0.337 |
|
| 2015 |
Cornford EM, Hyman S, Cornford ME, Chytrova G, Rhee J, Suzuki T, Yamagata T, Yamakawa K, Penichet ML, Pardridge WM. Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes. Journal of Drug Targeting. 1-10. PMID 26133964 DOI: 10.3109/1061186X.2015.1055569 |
0.357 |
|
| 2015 |
Pardridge WM. Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert Opinion On Therapeutic Targets. 19: 1059-72. PMID 25936389 DOI: 10.1517/14728222.2015.1042364 |
0.372 |
|
| 2015 |
Pardridge W. Targeted delivery of protein and gene medicines through the blood–brain barrier Clinical Pharmacology & Therapeutics. 97: 347-361. PMID 25669455 DOI: 10.1002/Cpt.18 |
0.53 |
|
| 2015 |
Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opinion On Drug Delivery. 12: 207-22. PMID 25138991 DOI: 10.1517/17425247.2014.952627 |
0.463 |
|
| 2014 |
Boado RJ, Lu JZ, Hui EK, Pardridge WM. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Molecular Pharmaceutics. 11: 2928-34. PMID 24949884 DOI: 10.1021/mp500258p |
0.453 |
|
| 2014 |
Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnology and Bioengineering. 111: 2317-25. PMID 24889100 DOI: 10.1002/bit.25289 |
0.384 |
|
| 2013 |
Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjugate Chemistry. 24: 1741-9. PMID 24059813 DOI: 10.1021/bc400319d |
0.517 |
|
| 2013 |
Sumbria RK, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Molecular Pharmaceutics. 10: 3507-13. PMID 23924247 DOI: 10.1021/mp400348n |
0.327 |
|
| 2013 |
Sumbria RK, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Molecular Pharmaceutics. 10: 1425-31. PMID 23410508 DOI: 10.1021/mp400004a |
0.412 |
|
| 2013 |
Boado RJ, Hui EK, Lu JZ, Pardridge WM. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjugate Chemistry. 24: 97-104. PMID 23249376 DOI: 10.1021/bc3005123 |
0.309 |
|
| 2013 |
Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnology and Bioengineering. 110: 1456-65. PMID 23192358 DOI: 10.1002/bit.24795 |
0.521 |
|
| 2012 |
Pardridge WM. Drug transport across the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 1959-72. PMID 22929442 DOI: 10.1038/jcbfm.2012.126 |
0.359 |
|
| 2012 |
Zhou QH, Boado RJ, Pardridge WM. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. Journal of Drug Targeting. 20: 715-9. PMID 22845843 DOI: 10.3109/1061186X.2012.712132 |
0.448 |
|
| 2012 |
Boado RJ, Hui EK, Lu JZ, Pardridge WM. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2021-5. PMID 22822036 DOI: 10.1124/dmd.112.046375 |
0.313 |
|
| 2012 |
Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 1933-8. PMID 22714051 DOI: 10.1038/jcbfm.2012.97 |
0.324 |
|
| 2012 |
Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods in Enzymology. 503: 269-92. PMID 22230573 DOI: 10.1016/B978-0-12-396962-0.00011-2 |
0.52 |
|
| 2012 |
Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 329-35. PMID 22065691 DOI: 10.1124/dmd.111.042903 |
0.49 |
|
| 2011 |
Boado RJ, Pardridge WM. The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier. Journal of Drug Delivery. 2011: 296151. PMID 22175028 DOI: 10.1155/2011/296151 |
0.378 |
|
| 2011 |
Zhou QH, Lu JZ, Hui EK, Boado RJ, Pardridge WM. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjugate Chemistry. 22: 1611-8. PMID 21707084 DOI: 10.1021/bc200174x |
0.38 |
|
| 2011 |
Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Molecular Pharmaceutics. 8: 1342-50. PMID 21667973 DOI: 10.1021/mp200136x |
0.341 |
|
| 2011 |
Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnology and Bioengineering. 108: 1954-64. PMID 21351076 DOI: 10.1002/bit.23118 |
0.498 |
|
| 2011 |
Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids and Barriers of the Cns. 8: 7. PMID 21349155 DOI: 10.1186/2045-8118-8-7 |
0.39 |
|
| 2011 |
Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. Brain Research. 1382: 315-20. PMID 21276430 DOI: 10.1016/j.brainres.2011.01.061 |
0.386 |
|
| 2011 |
Zhou QH, Fu A, Boado RJ, Hui EK, Lu JZ, Pardridge WM. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. Molecular Pharmaceutics. 8: 280-5. PMID 21141969 DOI: 10.1021/mp1003515 |
0.308 |
|
| 2011 |
Zhou QH, Boado RJ, Hui EK, Lu JZ, Pardridge WM. Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 71-6. PMID 20884844 DOI: 10.1124/dmd.110.036012 |
0.31 |
|
| 2011 |
Boado RJ, Hui EK, Lu JZ, Pardridge WM. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein. Biotechnology and Bioengineering. 108: 186-96. PMID 20803562 DOI: 10.1002/bit.22907 |
0.407 |
|
| 2010 |
Pardridge WM. Biologic TNFα-inhibitors that cross the human blood-brain barrier. Bioengineered Bugs. 1: 231-4. PMID 21327054 DOI: 10.4161/bbug.1.4.12105 |
0.499 |
|
| 2010 |
Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Molecular Pharmaceutics. 7: 2148-55. PMID 20860349 DOI: 10.1021/mp1001763 |
0.424 |
|
| 2010 |
Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Research. 1352: 208-13. PMID 20599807 DOI: 10.1016/j.brainres.2010.06.059 |
0.396 |
|
| 2010 |
Pardridge WM. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harbor Protocols. 2010: pdb.prot5407. PMID 20360361 DOI: 10.1101/pdb.prot5407 |
0.502 |
|
| 2010 |
Boado RJ, Hui EK, Lu JZ, Pardridge WM. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. The Journal of Pharmacology and Experimental Therapeutics. 333: 961-9. PMID 20233799 DOI: 10.1124/jpet.109.165092 |
0.402 |
|
| 2010 |
Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. Journal of Biotechnology. 146: 84-91. PMID 20100527 DOI: 10.1016/j.jbiotec.2010.01.011 |
0.357 |
|
| 2010 |
Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 566-72. PMID 20075191 DOI: 10.1124/dmd.109.031534 |
0.433 |
|
| 2010 |
Pardridge WM. Biopharmaceutical drug targeting to the brain. Journal of Drug Targeting. 18: 157-67. PMID 20064077 DOI: 10.3109/10611860903548354 |
0.492 |
|
| 2010 |
Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Molecular Pharmaceutics. 7: 237-44. PMID 19921848 DOI: 10.1021/mp900235k |
0.345 |
|
| 2010 |
Boado RJ, Pardridge WM. Genetic engineering of IgG-glucuronidase fusion proteins. Journal of Drug Targeting. 18: 205-11. PMID 19827970 DOI: 10.3109/10611860903353362 |
0.402 |
|
| 2010 |
Boado RJ, Lu JZ, Hui EK, Pardridge WM. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnology and Bioengineering. 105: 627-35. PMID 19816967 DOI: 10.1002/bit.22576 |
0.428 |
|
| 2009 |
Boado RJ, Pardridge WM. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 2299-304. PMID 19741036 DOI: 10.1124/dmd.109.028787 |
0.504 |
|
| 2009 |
Hui EK, Boado RJ, Pardridge WM. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Molecular Pharmaceutics. 6: 1536-43. PMID 19624167 DOI: 10.1021/mp900103n |
0.383 |
|
| 2009 |
Pardridge WM, Boado RJ. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharmaceutical Research. 26: 2227-36. PMID 19609743 DOI: 10.1007/s11095-009-9939-6 |
0.429 |
|
| 2009 |
Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnology and Bioengineering. 102: 1251-8. PMID 18942151 DOI: 10.1002/bit.22135 |
0.382 |
|
| 2008 |
Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Molecular Pharmaceutics. 5: 1037-43. PMID 19434854 DOI: 10.1021/MP800113G |
0.427 |
|
| 2008 |
Pardridge WM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjugate Chemistry. 19: 1327-38. PMID 18547095 DOI: 10.1021/bc800148t |
0.487 |
|
| 2008 |
Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjugate Chemistry. 19: 731-9. PMID 18278853 DOI: 10.1021/bc7004076 |
0.313 |
|
| 2008 |
Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR. Strategies to advance translational research into brain barriers. The Lancet. Neurology. 7: 84-96. PMID 18093565 DOI: 10.1016/S1474-4422(07)70326-5 |
0.511 |
|
| 2008 |
Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnology and Bioengineering. 100: 387-96. PMID 18080333 DOI: 10.1002/bit.21764 |
0.406 |
|
| 2008 |
Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnology and Bioengineering. 99: 475-84. PMID 17680664 DOI: 10.1002/bit.21602 |
0.43 |
|
| 2008 |
Chu C, Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics and cloning of a novel organic anion transporter. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 28: 291-301. PMID 17667996 DOI: 10.1038/sj.jcbfm.9600538 |
0.352 |
|
| 2008 |
Zhang Y, Wang Y, Boado RJ, Pardridge WM. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharmaceutical Research. 25: 400-6. PMID 17602284 DOI: 10.1007/s11095-007-9357-6 |
0.377 |
|
| 2007 |
Xia CF, Zhang Y, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharmaceutical Research. 24: 2309-16. PMID 17926121 DOI: 10.1007/s11095-007-9460-8 |
0.472 |
|
| 2007 |
Pardridge WM. Brain drug development and brain drug targeting. Pharmaceutical Research. 24: 1729-32. PMID 17629776 DOI: 10.1007/s11095-007-9387-0 |
0.408 |
|
| 2007 |
Pardridge WM. Drug targeting to the brain. Pharmaceutical Research. 24: 1733-44. PMID 17554607 DOI: 10.1007/s11095-007-9324-2 |
0.518 |
|
| 2007 |
Pardridge WM. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. Journal of Controlled Release : Official Journal of the Controlled Release Society. 122: 345-8. PMID 17512078 DOI: 10.1016/j.jconrel.2007.04.001 |
0.462 |
|
| 2007 |
Xia CF, Chu C, Li J, Wang Y, Zhang Y, Boado RJ, Pardridge WM. Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes. The Journal of Gene Medicine. 9: 605-12. PMID 17471587 DOI: 10.1002/jgm.1046 |
0.473 |
|
| 2007 |
Pardridge WM. shRNA and siRNA delivery to the brain. Advanced Drug Delivery Reviews. 59: 141-52. PMID 17434235 DOI: 10.1016/j.addr.2007.03.008 |
0.419 |
|
| 2007 |
Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjugate Chemistry. 18: 447-55. PMID 17315944 DOI: 10.1021/bc060349x |
0.433 |
|
| 2007 |
Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnology and Bioengineering. 97: 1376-86. PMID 17286273 DOI: 10.1002/bit.21369 |
0.393 |
|
| 2007 |
Pardridge WM. Blood-brain barrier genomics. Stroke. 38: 686-90. PMID 17261716 DOI: 10.1161/01.STR.0000247887.61831.74 |
0.515 |
|
| 2007 |
Pardridge WM. Blood-brain barrier delivery. Drug Discovery Today. 12: 54-61. PMID 17198973 DOI: 10.1016/j.drudis.2006.10.013 |
0.41 |
|
| 2007 |
Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnology and Bioengineering. 96: 381-91. PMID 16937408 DOI: 10.1002/bit.21120 |
0.376 |
|
| 2006 |
Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Discovery Medicine. 6: 139-43. PMID 17234133 |
0.454 |
|
| 2006 |
Zhang Y, Pardridge WM. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Research. 1111: 227-9. PMID 16884698 DOI: 10.1016/j.brainres.2006.07.005 |
0.3 |
|
| 2006 |
Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Current Opinion in Pharmacology. 6: 494-500. PMID 16839816 DOI: 10.1016/j.coph.2006.06.001 |
0.46 |
|
| 2006 |
Chu C, Zhang Y, Boado RJ, Pardridge WM. Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. Pharmaceutical Research. 23: 1586-90. PMID 16779704 DOI: 10.1007/s11095-006-0274-x |
0.447 |
|
| 2005 |
Pardridge WM. Molecular biology of the blood-brain barrier. Molecular Biotechnology. 30: 57-70. PMID 15805577 DOI: 10.1385/MB:30:1:057 |
0.477 |
|
| 2005 |
Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. The Journal of Pharmacology and Experimental Therapeutics. 313: 1075-81. PMID 15718287 DOI: 10.1124/jpet.104.082974 |
0.391 |
|
| 2005 |
Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 129-38. PMID 15717064 DOI: 10.1602/neurorx.2.1.129 |
0.357 |
|
| 2005 |
Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 3-14. PMID 15717053 DOI: 10.1602/neurorx.2.1.3 |
0.443 |
|
| 2005 |
Pardridge WM. The blood-brain barrier and neurotherapeutics. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 1-2. PMID 15717052 DOI: 10.1602/neurorx.2.1.1 |
0.435 |
|
| 2004 |
Suzuki T, Zhang Y, Zhang YF, Schlachetzki F, Pardridge WM. Imaging gene expression in regional brain ischemia in vivo with a targeted [111in]-antisense radiopharmaceutical. Molecular Imaging. 3: 356-63. PMID 15802053 DOI: 10.1162/1535350042973535 |
0.475 |
|
| 2004 |
Suzuki T, Wu D, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 1766-75. PMID 15471847 |
0.465 |
|
| 2004 |
Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opinion On Biological Therapy. 4: 1103-13. PMID 15268677 DOI: 10.1517/14712598.4.7.1103 |
0.346 |
|
| 2004 |
Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer Clinical Cancer Research. 10: 3667-3677. PMID 15173073 DOI: 10.1158/1078-0432.CCR-03-0740 |
0.36 |
|
| 2004 |
Schlachetzki F, Zhang Y, Boado RJ, Pardridge WM. Gene therapy of the brain: the trans-vascular approach. Neurology. 62: 1275-81. PMID 15111662 DOI: 10.1212/01.WNL.0000120551.38463.D9 |
0.493 |
|
| 2004 |
Pardridge WM. Log(BB), PS products and in silico models of drug brain penetration. Drug Discovery Today. 9: 392-3. PMID 15081955 DOI: 10.1016/S1359-6446(04)03065-X |
0.342 |
|
| 2004 |
Zhang Y, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Human Gene Therapy. 15: 339-50. PMID 15053859 DOI: 10.1089/104303404322959498 |
0.341 |
|
| 2004 |
Pardridge WM. Holy grails and in vitro blood-brain barrier models. Drug Discovery Today. 9: 258. PMID 15003241 DOI: 10.1016/S1359-6446(03)03003-4 |
0.407 |
|
| 2004 |
Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Molecular Interventions. 3: 90-105, 51. PMID 14993430 DOI: 10.1124/mi.3.2.90 |
0.446 |
|
| 2004 |
Boado RJ, Li JY, Pardridge WM. Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Pediatric Research. 55: 557-60. PMID 14764922 DOI: 10.1203/01.PDR.0000113461.07950.72 |
0.411 |
|
| 2004 |
Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. The Journal of Gene Medicine. 5: 1039-45. PMID 14661179 DOI: 10.1002/jgm.449 |
0.307 |
|
| 2004 |
Schlachetzki F, Pardridge WM. P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport. 14: 2041-6. PMID 14600494 DOI: 10.1097/00001756-200311140-00007 |
0.361 |
|
| 2003 |
Pardridge WM. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. Current Opinion in Drug Discovery & Development. 6: 683-91. PMID 14579518 |
0.477 |
|
| 2003 |
Shusta EV, Li JY, Boado RJ, Pardridge WM. The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. Neuroreport. 14: 1861-5. PMID 14534436 DOI: 10.1097/00001756-200310060-00021 |
0.654 |
|
| 2003 |
Pardridge WM. Molecular biology of the blood-brain barrier. Methods in Molecular Medicine. 89: 385-99. PMID 12958435 DOI: 10.1385/1-59259-419-0:385 |
0.415 |
|
| 2003 |
Boado RJ, Li JY, Tsukamoto H, Pardridge WM. Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. Journal of Neurochemistry. 85: 1037-42. PMID 12716435 DOI: 10.1046/j.1471-4159.2003.01757.x |
0.31 |
|
| 2003 |
Pardridge WM. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Advances in Experimental Medicine and Biology. 513: 397-430. PMID 12575830 DOI: 10.1007/978-1-4615-0123-7_15 |
0.421 |
|
| 2003 |
Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 11-8. PMID 12573613 DOI: 10.1016/s1525-0016(02)00018-7 |
0.489 |
|
| 2003 |
Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Human Gene Therapy. 14: 1-12. PMID 12573054 DOI: 10.1089/10430340360464660 |
0.375 |
|
| 2003 |
Pardridge WM. Neurotrophins, neuroprotection and the blood-brain barrier. Current Opinion in Investigational Drugs (London, England : 2000). 3: 1753-7. PMID 12528312 |
0.441 |
|
| 2003 |
Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 67-72. PMID 12095305 DOI: 10.1006/mthe.2002.0633 |
0.404 |
|
| 2002 |
Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 36: 555-8. PMID 12441045 DOI: 10.1016/s0896-6273(02)01054-1 |
0.489 |
|
| 2002 |
Li JY, Boado RJ, Pardridge WM. Rat blood-brain barrier genomics. II. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 22: 1319-26. PMID 12439289 DOI: 10.1097/01.WCB.0000040944.89393.0f |
0.483 |
|
| 2002 |
Shusta EV, Zhu C, Boado RJ, Pardridge WM. Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. Journal of Neuropathology and Experimental Neurology. 61: 597-604. PMID 12125738 DOI: 10.1093/Jnen/61.7.597 |
0.624 |
|
| 2002 |
Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nature Reviews. Drug Discovery. 1: 131-9. PMID 12120094 DOI: 10.1038/nrd725 |
0.523 |
|
| 2002 |
Lee HJ, Boado RJ, Braasch DA, Corey DR, Pardridge WM. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 948-56. PMID 12097468 |
0.312 |
|
| 2002 |
Shusta EV, Boado RJ, Pardridge WM. Vascular proteomics and subtractive antibody expression cloning. Molecular & Cellular Proteomics : McP. 1: 75-82. PMID 12096143 DOI: 10.1074/Mcp.T100008-Mcp200 |
0.594 |
|
| 2002 |
Wu D, Song BW, Vinters HV, Pardridge WM. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. Journal of Drug Targeting. 10: 239-45. PMID 12075825 DOI: 10.1080/10611860290022679 |
0.462 |
|
| 2002 |
Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. Journal of Neurochemistry. 81: 203-6. PMID 12067234 DOI: 10.1046/j.1471-4159.2002.00840.x |
0.509 |
|
| 2002 |
Song BW, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. The Journal of Pharmacology and Experimental Therapeutics. 301: 605-10. PMID 11961063 DOI: 10.1124/Jpet.301.2.605 |
0.412 |
|
| 2002 |
Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. The Journal of Gene Medicine. 4: 183-94. PMID 11933219 DOI: 10.1002/jgm.255 |
0.373 |
|
| 2002 |
Shusta EV, Boado RJ, Mathern GW, Pardridge WM. Vascular genomics of the human brain. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 22: 245-52. PMID 11891429 DOI: 10.1097/00004647-200203000-00001 |
0.641 |
|
| 2002 |
Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 22: 223-31. PMID 11823720 DOI: 10.1097/00004647-200202000-00010 |
0.38 |
|
| 2002 |
Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Archives of Neurology. 59: 35-40. PMID 11790228 DOI: 10.1001/archneur.59.1.35 |
0.395 |
|
| 2001 |
Pardridge W. Gene targeting technology and gene therapy of the brain. Drug Discovery Today. 6: 125-126. PMID 11165183 DOI: 10.1016/S1359-6446(00)01652-4 |
0.426 |
|
| 2000 |
Terasaki T, Pardridge W. Preface: Targeted Drug Delivery to the Brain (Blood-Brain Barrier, Efflux, Endothelium, Biological Transport) Journal of Drug Targeting. 8: 353-355. PMID 11328661 DOI: 10.3109/10611860008997911 |
0.474 |
|
| 1986 |
Steingold KA, Cefalu W, Pardridge W, Judd HL, Chaudhuri G. Enhanced hepatic extraction of estrogens used for replacement therapy. The Journal of Clinical Endocrinology and Metabolism. 62: 761-6. PMID 3949955 DOI: 10.1210/Jcem-62-4-761 |
0.377 |
|
| Show low-probability matches. |